October 29, 2020
A new European multi-stakeholder partnership – INNODIA – has been launched to advance understanding of type 1 diabetes and develop tools and technologies that will allow health professionals to predict, evaluate and prevent the onset and progression of the condition. For people living with type 1 diabetes, this would mean the ability to predict the rate at which their condition will progress. The knowledge and tools generated by INNODIA will help researchers to optimize the design of clinical trials for treatments that will hopefully prevent and cure this potentially debilitating condition that affects around 10% of people living with diabetes.
INNODIA is a consortium of 40 European partners funded by the European Commission. It brings together a large team of international academic researchers and the most important pharmaceutical companies active in diabetes research.
The needs and concerns of people with type 1 diabetes are at the heart of INNODIA. A Patient Advisory Committee (PAC) has been set up to give a voice to the experiences and desires of people living with type 1 diabetes and their family members. This is intended to ensure close alignment with the goals and strategy of INNODIA and that the specific outcomes of the project have the potential to improve the lives of people affected. The PAC consists of of nine people with type 1 diabetes or close family members of people with the condition, from throughout the European Union.
A key focus of INNODIA is conducting clinical intervention studies to facilitate the development of novel treatments to prevent and cure type 1 diabetes. The Innovative Medicines Initiative (IMI) of the European Commission has approved an additional section of work on biomarkers and prevention of type 1 diabetes within INNODIA. This additional section is called ‘INNODIA HARVEST’, and is aimed at ‘harvesting’ the findings that have already arisen from the project.